Unicycive Therapeutics Free Cash Flow (FCF) History (UNCY)
Unicycive Therapeutics reported −$31.3M in free cash flow for fiscal 2025, a decrease of $2.7M from the previous fiscal year.
View full Unicycive Therapeutics company overviewUnicycive Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$31.3M | −$2.7M | — | — |
| 2024 | 2024-12-31 | −$28.6M | −$10.4M | — | — |
| 2023 | 2023-12-31 | −$18.3M | −$2.6M | — | −2710.37% |
| 2022 | 2022-12-31 | −$15.7M | −$9.9M | — | −1645.95% |
| 2021 | 2021-12-31 | −$5.8M | — | — | — |
Unicycive Therapeutics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.6M | $821,000 | — | — |
| Q1 2026 | 2026-03-31 | −$6.2M | $2.7M | — | — |
| Q4 2025 | 2025-12-31 | −$8.0M | −$1.5M | — | — |
| Q3 2025 | 2025-09-30 | −$6.0M | $3.3M | — | — |
| Q2 2025 | 2025-06-30 | −$8.4M | −$2.1M | — | — |
| Q1 2025 | 2025-03-31 | −$8.9M | −$2.5M | — | — |
| Q4 2024 | 2024-12-31 | −$6.6M | — | — | — |
| Q3 2024 | 2024-09-30 | −$9.3M | −$4.9M | — | — |
| Q2 2024 | 2024-06-30 | −$6.3M | — | — | — |
| Q1 2024 | 2024-03-31 | −$6.5M | — | — | — |
| Q3 2023 | 2023-09-30 | −$4.4M | −$859,000 | — | — |
| Q4 2022 | 2022-12-31 | −$6.1M | — | — | — |
| Q3 2022 | 2022-09-30 | −$3.6M | — | — | −374.66% |
| Q2 2022 | 2022-06-30 | −$3.0M | — | — | — |
| Q1 2022 | 2022-03-31 | −$3.0M | — | — | — |
Unicycive Therapeutics free cash flow growth trends
Unicycive Therapeutics's latest reported quarter, Q2 2026, generated −$7.6M in free cash flow, an increase of $821,000 year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Unicycive Therapeutics source filings ↗Community posts
Unicycive resubmits kidney-drug application with new manufacturer data
Unicycive ($UNCY) resubmitted its US application for oxylanthanum carbonate, an investigational oral phosphate binder for dialysis patients with chronic kidney disease. The package includes manufacturing and quality data from a new third-pa ...